Listen to leading experts discuss the new Scientific Statement from the American Heart Association, “Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease,” where two newer groups of medications prescribed primarily for Type 2 diabetes treatment (SGLT2 inhibitors and GLP-1 receptor agonists) could significantly reduce risks associated with chronic kidney disease (CKD) and heart disease.
Creators & Guests
We don't know anything about the creators of this episode yet. You can add them yourself so they can be credited for this and other podcasts.
This episode hasn't been reviewed yet. You can add a review to show others what you thought.
This podcast, its content, and its artwork are not owned by, affiliated with, or endorsed by Podchaser.